Streetbeat News

EVFM

Evofem Biosciences Inc

CEO

Saundra Pelletier

Employees

147

Industry

Pharmaceutical Preparation Manufacturing

Evofem Biosciences, Inc., is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company's first commercial product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The Company is evaluating EVO100 in a Phase 3 clinical trial, 'EVOGUARD,' for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Evofem Biosciences is highlighting the potential impact of GLP-1 medications on oral contraceptive effectiveness and promoting Phexxi as a non-oral contraceptive solution.

Portfolio Pulse from Benzinga Newsdesk

August 20, 2024 | 12:19 pm

Aditxt received a notice on April 26 from Evofem, stating that Evofem is terminating their merger agreement due to Aditxt's failure to provide the initial parent equity investment as required.

Portfolio Pulse from Charles Gross

May 03, 2024 | 10:05 am

France has made history by becoming the first country to explicitly include abortion rights in its constitution, according to a report by the Washington Post. This landmark decision could have implications for companies involved in women's health and reproductive products.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 5:53 pm

Laidlaw & Co. analyst Yale Jen has downgraded Evofem Biosciences (EVFM) from Buy to Hold, indicating a change in the firm's outlook on the stock.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 9:25 am

Aditxt Inc (NASDAQ:ADTX) is acquiring Evofem Biosciences Inc (OTC:EVFM) for approximately $100 million through stock issuance and debt assumption. Evofem, known for its FDA-approved contraceptive gel Phexxi, will see its shareholders receive Aditxt common and preferred stock. Aditxt will also provide a loan to Evofem and cover legal costs. The transaction is expected to close in the first half of 2024. ADTX shares surged 112.80% to $8.08 following the announcement.

Portfolio Pulse from Vandana Singh

December 12, 2023 | 3:19 pm

Aditxt, Inc. (NASDAQ:ADTX) has entered into a definitive agreement to acquire Evofem Biosciences, Inc. (OTCQB:EVFM) for approximately $100 million, consisting of common and preferred stock issuance and assumption of senior indebtedness. Evofem's Phexxi, a non-hormonal contraceptive gel, has seen $13.4 million in net sales for the first nine months of 2023. The acquisition aims to expand into the global non-hormonal birth control market, projected to grow to $52.2 billion by 2031. The transaction is expected to close in the first half of 2024, subject to stockholder approvals and other conditions.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 1:34 pm

Evofem Biosciences announced that Padagis will not seek FDA approval to market a generic version of Phexxi until Evofem's Phexxi patents expire. Evofem has Phexxi patent protection through 2033.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 12:49 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.